1994
DOI: 10.1073/pnas.91.3.969
|View full text |Cite
|
Sign up to set email alerts
|

Humanization of murine monoclonal antibodies through variable domain resurfacing.

Abstract: Two murine monoclonal antibodies, N901

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
99
0
2

Year Published

1997
1997
2017
2017

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 187 publications
(104 citation statements)
references
References 39 publications
3
99
0
2
Order By: Relevance
“…At first, eleven camelid VHH framework residues outside framework-2 of NbBcII10 were humanized to mimic the DP-47 sequence (Ser-12 3 Leu, Ala-15 3 Pro, Thr-24 3 Ala, Ala-83 3 Ser, Val-87 3 Leu, Thr-88 3 Tyr, Asn-93 3 Ser, Lys-95 3 Arg, Pro-96 3 Ala, Ile-101 3 Val, and Gln-123 3 Leu) (h-NbBcII10). These solvent-exposed residues are expected to have only minor influence on the CDR conformation (43,44), which is confirmed by the wild-type-like binding behavior of h-NbBcII10 (Table 3A and Fig. 2).…”
supporting
confidence: 52%
“…At first, eleven camelid VHH framework residues outside framework-2 of NbBcII10 were humanized to mimic the DP-47 sequence (Ser-12 3 Leu, Ala-15 3 Pro, Thr-24 3 Ala, Ala-83 3 Ser, Val-87 3 Leu, Thr-88 3 Tyr, Asn-93 3 Ser, Lys-95 3 Arg, Pro-96 3 Ala, Ile-101 3 Val, and Gln-123 3 Leu) (h-NbBcII10). These solvent-exposed residues are expected to have only minor influence on the CDR conformation (43,44), which is confirmed by the wild-type-like binding behavior of h-NbBcII10 (Table 3A and Fig. 2).…”
supporting
confidence: 52%
“…In addition, a humanized derivative of the previously described anti-FRa antibody Mov19 (4, 37, 38), denoted M9346A, was prepared and added to the group of antibodies to be evaluated. The antibodies were humanized by variable domain resurfacing (39).…”
Section: Selection Of a Fra-binding Antibody For A Maytansinoid Adcmentioning
confidence: 99%
“…22 Murine antibodies were humanized by variable domain resurfacing. 23 Conjugation of antibodies to the DM1 maytansinoid was performed using the cross-linking agent N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) as described previously. 24 Rituximab and alemtuzumab were obtained from commercial sources.…”
Section: Antibody and Conjugate Generationmentioning
confidence: 99%